Pharmacological Management of Delirium in the Intensive Care Unit: A Randomized Pragmatic Clinical Trial

J Am Geriatr Soc. 2019 May;67(5):1057-1065. doi: 10.1111/jgs.15781. Epub 2019 Jan 25.

Abstract

Background/objective: Delirium in the intensive care units (ICUs) is prevalent, with both delirium duration and delirium severity associated with adverse outcomes. We designed a pragmatic trial to test the efficacy of a pharmacological management of delirium (PMD) bundle in improving delirium/coma-free days and reducing delirium severity among ICU patients.

Design: A randomized pragmatic clinical trial.

Setting: Medical, surgical, and progressive ICUs of three tertiary care hospitals.

Participants: A total of 351 critically ill patients.

Intervention: A multicomponent PMD bundle consisting of reducing the exposure to 20 definite anticholinergic medications and benzodiazepines and prescribing low-dose haloperidol.

Measurements: The primary outcomes were delirium/coma-free days, measured through the Richmond Agitation-Sedation Scale and the Confusion Assessment Method for the ICU (CAM-ICU), and delirium severity, measured through Delirium Rating Scale-Revised-98 and the CAM-ICU-7. Secondary outcomes were in-hospital and posthospital discharge 30-day mortality, ICU and hospital lengths of stay, and delirium-related hospital complications.

Results: We randomized 351 critically ill delirious patients (mean age = 59.3 years [SD = 16.9 years]; 52% female, 42% African Americans) to receive the PMD bundle or usual care. There were no significant differences in median delirium/coma-free days at day 8 (PMD vs usual care = 4 [interquartile range {IQR} = 2-7] days vs 5 [IQR = 1-7] days; P = .888) or at day 30 (PMD vs usual care = 26 [IQR 19-29] days vs 26 [IQR, 14-29] days; P = .991). There were no significant differences for decrease in delirium severity at day 8, but at hospital discharge, the intervention group showed a greater reduction in delirium severity (mean decrease in CAM-ICU-7 score for PMD vs usual care = 3.2 [SD = 3.3] vs 2.5 [SD = 3.2]; P = .046). No differences were observed between groups for ICU and hospital lengths of stay, mortality, and delirium-related hospital complications. Similar results were observed when analyses were limited to patients 65 years or older and 75 years or older.

Conclusion and relevance: Implementing the PMD bundle in the ICU did not reduce delirium duration or severity among critically ill patients.

Trial registration: clinicaltrials.gov Identifier: NCT00842608. J Am Geriatr Soc 67:1057-1065, 2019.

Keywords: benzodiazepine; delirium; haloperidol; randomized trial.

Publication types

  • Multicenter Study
  • Pragmatic Clinical Trial
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antipsychotic Agents / administration & dosage
  • Benzodiazepines / administration & dosage*
  • Cholinergic Antagonists / administration & dosage*
  • Critical Illness / mortality
  • Critical Illness / therapy*
  • Delirium / drug therapy*
  • Delirium / epidemiology
  • Delirium / etiology
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Haloperidol / administration & dosage*
  • Humans
  • Intensive Care Units*
  • Length of Stay / trends
  • Male
  • Middle Aged
  • Prevalence
  • Retrospective Studies
  • Survival Rate / trends
  • United States / epidemiology

Substances

  • Antipsychotic Agents
  • Cholinergic Antagonists
  • Benzodiazepines
  • Haloperidol

Associated data

  • ClinicalTrials.gov/NCT00842608